“What is the advantage of waiting until ESMO in May to release the TNBC data, as opposed to a press release today that says specifically that X number of patients are alive today at 4 times the overall survival rate of current standard of care?”

This one is easy. ESMO guidelines limiting participants from publishing data before conference.

Letter to shareholders…

“As previously announced, we’ve submitted our findings as an abstract to the European Society for Medical Oncology meeting in Munich, Germany in May 2025. We are eager to share additional insights into the apparent mechanism behind the survival outcomes and will do so once appropriate and in compliance with pre-conference publication and announcement allowances.”